Profiles of COVID-19 clinical trials in the Chinese Clinical Trial Registry

Figures & data

Figure 1. The number of registered COVID-19 clinical trials, ranging from January 2020 to April 2020 in China. The X-axis is the trend of the registration date. The Y-axis is the number of COVID-19 clinical trials, and divided into two types of interventions. TCM: traditional Chinese medicine. WM: western medicine.

Table 1. General characteristic of COVID-19 clinical trials from ChiCTR.

Variables	No (%)
Ethics approval (n = 617)
Yes	521 (84.4)
No	96 (15.6)
The primary purpose (n = 617)
Treatment	265 (42.9)
Prevention	93 (15.1)
Other purposes	259 (42.0)
Clinical trial phase (interventional studies, n = 265)
Phase I	6 (2.2)
Phase I/ phase II	14 (5.3)
Phase II	15 (5.7)
Phase II / phase III	3 (1.1)
Phase III	4 (1.5)
Phase IV	108 (40.8)
Not applicable	115 (43.4)
Enrolment (interventional studies, n = 265)
0–99	121 (45.7)
100–499	114 (43.0)
500–999	14 (5.3)
≥1000	11 (4.2)
Not available	5 (1.8)
Number of facilities (interventional studies, n = 265)
Single facility	176 (66.4)
2–5 facilities	72 (27.2)
6–10 facilities	15 (5.6)
>10 facilities	2 (0.8)
Lead sponsor (interventional studies, n = 265)
Universities/hospitals	226 (85.3)
Industry	39 (14.7)
Overall status (interventional studies, n = 265)
Recruiting	131 (49.4)
Not yet recruiting	105 (39.6)
Suspended	27 (10.2)
Completed	2 (0.8)

Table 2. Design of 265 interventional COVID-19 clinical trials.

Variables	No (%) (n = 265)
Allocation
Randomized	157 (59.2)
Non-randomized	108 (40.8)
Blinding
Open-label	247 (93.2)
Single-blind	5 (1.9)
Double-blind	12 (4.5)
Triple-blind	1 (0.4)
Type of participants
Confirmed case	78 (29.4)
Common case	31 (11.7)
Wild case /common case	30 (11.3)
Wild case /severe case	24 (9.1)
Severe case	19 (7.2)
Severe case /critical case	18 (6.8)
Common/severe case	16 (6.0)
Rehabilitation case	11(4.2)
Critical/suspected case	9 (3.4)
Wild case	9 (3.4)
Suspected/confirmed case	8 (3.0)
Suspected case	7 (2.6)
Healthy people	5 (1.9)
Number of primary outcomes
1	175 (66.0)
2–5	73 (27.5)
6–9	15 (5.7)
>10	2 (0.8)

Table 3. Overview of candidate interventions from 265 COVID-19 clinical trials

Intervention Categories	Intervention Subcategories	No (%) (n = 265)
Anti-malarial drugs		43 (16.2)
	Chloroquine phosphate	30
	Hydroxychloroquine	7
	Phosphoric chloroquine	4
	Chloroquine	2
Anti-viral drugs		29 (10.9)
	Ritonavir plus lopinavir	8
	Recombinant interferon	4
	Favipiravir	4
	Azzedine	3
	Baloxavir marboxil	2
	Darunavir	2
	Ganovo	2
	ASC09/ritonavir	1
	Arbidol hydrochloride	1
	Carrimycin	1
	Triazavirin	1
Stem cells		16 (6.0)
	Mesenchymal stem cells	9
	Umbilical cord mesenchymal stem cell-conditioned medium	1
	Umbilical cord blood mononuclear cells	1
	Menstrual blood-derived stem cells	1
	Human menstrual blood-derived stem cells	1
	NK cells and mesenchymal stem cells	1
	Umbilical cord blood plasma	1
	Cord blood mesenchymal stem cells	1
Immunomodulators		13 (4.9)
	Convalescent plasma	11
	CMAB806 (IL-6)	1
	NLRP Inflammasome inhibitor (Tranilast)	1
Monoclonal antibodies		6 (2.3)
	Tocilizumab	2
	Adalimumab	1
	Ixekizumab	1
	Camrelizumab	1
	PD-1	1
Corticosteroid	Methylprednisolone	4 (1.5)
Vaccine		4 (1.5)
	Vaccine (adenoviral vector)	2
	Vaccine (vero cells)	1
	DC vaccine	1